Limitations, agreements, and source contact

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab · Source last updated 2026-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Accrual ended early based on planned interim analysis, but the study was completed with existing participants.

point Of Contact

email

jill.gilbert@vanderbilt.edu

organization

Vanderbilt Ingram Cancer Center

phone

615-343-4677

title

Jill Gilbert, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice